TAPAS
Financiado
Taking blood apart by sound
Separation of blood components is of high importance in healthcare and often require fractionation of blood in its subcomponents by centrifugation. There are several scenarios that calls for improved resolution:
1. When blood is...
Separation of blood components is of high importance in healthcare and often require fractionation of blood in its subcomponents by centrifugation. There are several scenarios that calls for improved resolution:
1. When blood is drawn from a donor and a specific cell type is extracted while returning remaining blood components.
2. In cancer immunotherapy where T-cells are isolated from the blood and then genetically reprogrammed to be re-infused in the patient where they seek up and destroy cancer cells.
3. Circulating tumor cells, which are involved in the process of formation of metastases in cancer patients, can be detected and monitored by extracting cancer cells in large volumes of blood.
4. Improving the quality and reducing the number of manual procedures in diagnostic instrumentation that analyzes blood.
Centrifugation has the fundamental drawback of having rotating parts, and thereby taking up space and being difficult to implement for flow-through processing which is desirable both for integration in analytical equipment and for processing blood for continuous re-infusion into a person.
We will investigate an alternative to centrifugation wherein blood components are separated by a sound field. Cells will be separated based on differences in density and size while flowing through an acoustic separator module. Recent ERC-funded research indicates that this approach is feasible, but three scientific questions has been identified with fundamental impact on the commercial potential of this technology:
1. How selectively can sub-groups of blood cells be separated by acoustic separation?
2. Can acoustic separation be scaled for high throughput applications?
3. Can acoustic separation affect blood cells?
To address this, my team will design and build two prototype systems for whole blood processing and evaluate the quality and throughput of the separation with the ultimate goal of bringing this technology to the market for the benefit of society.
ver más
Duración del proyecto: 25 meses
Fecha Inicio: 2022-09-26
Fecha Fin: 2024-10-31
Fecha Fin: 2024-10-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-POC2:
ERC PROOF OF CONCEPT GRANTS2
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
LUNDS UNIVERSITET
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5